At Deepbridge, we offer tax-efficient investment opportunities into a portfolio of exciting growth-focused companies through the Deepbridge Technology Growth EIS Fund.

An example of the types of exciting companies we support is AlgaeCytes, a biomanufacturing company aiming to make premium vegan-friendly, traceable ingredients from natural, selectively cultivated microalgae and sell the ingredients (initially B2B) for use in health and wellness products. 

Deepbridge is currently seeking to provide AlgaeCytes with a further funding, in order to support the development of its first commercial plant. As such, AlgaeCytes could be one of the companies included in an investor’s Deepbridge Technology Growth EIS portfolio. 

What does AlgaeCytes do? 

AlgaeCytes, using its patented and proprietary technology, is producing ethical, high-grade, vegan EPA and DHA omega-3 oils, and associated bioactive products derived from freshwater algae. The Company is focused on B2B ingredient sales to the healthcare, nutraceutical, personal care, and pharmaceutical product markets. 

Omega-3 oils are increasingly in high demand within a multitude of sectors including healthcare, food and drink, sports, cosmetics, personal and oral care industries, due to their perceived many health-promoting qualities, as reported by the company itself. The human body cannot naturally produce omega-3 oils and so is traditionally sourced from wild-catch deep sea fish, other marine animals, algae, and vegetables (including flaxseed). 

AlgaeCytes’ primary product is the omega-3 EPA oils. EPA oils are recognised to enhance heart, cardiovascular, neurological, and skin health, and lessen inflammation. Other products produced by the Company include beta-carotene (vitamin A source) and an agricultural crop bio-stimulant from algae. 

Click here to find out more about AlgaeCytes. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).   

What makes AlgaeCytes an exciting investment opportunity? 

• Secured all external funding, including State Aid and private equity funding to commence development work at their first commercial site in Dessau, Germany. 

• The facility aims to start production by mid-2025, marking its first commercial sales. 

• This project is supported by more than £65m of capital and numerous regulatory consents. 

• Continued to make considerable progress in securing Letters of Intent for the offtake of its commercial product. 

• Working to explore other future production plant locations, with representatives from multiple countries expressing interest in locating a site and supporting future funding. 

Don’t forget: electronic application forms can be requested via the Deepbridge website here. 

If you want to learn more about Deepbridge and how to invest in our funds, please contact us here.